MARKET

UTHR

UTHR

Utd Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

235.83
+11.05
+4.92%
After Hours: 236.32 +0.49 +0.21% 19:13 05/27 EDT
OPEN
226.12
PREV CLOSE
224.78
HIGH
236.06
LOW
223.02
VOLUME
544.09K
TURNOVER
0
52 WEEK HIGH
236.06
52 WEEK LOW
158.38
MARKET CAP
10.68B
P/E (TTM)
16.33
1D
5D
1M
3M
1Y
5Y
Hot Stocks: DELL jumps on earnings; IOVA, SWTX plunge on clinical data; UTHR sets high
The major U.S. equity averages scored another day of notable gains, continuing a rebound that started midway through the week. The Nasdaq led the charge with a 3% advance, as
Seekingalpha · 1d ago
Liquidia initiated Buy at BofA on upcoming rival to United Therapeutics
Bank of America launched its coverage on Liquidia Corporation (NASDAQ:LQDA) with a Buy rating after the developer of lung disease drug Yutrepia recently suffered a major setback when a rival
Seekingalpha · 2d ago
Short Volatility Alert: United Therapeutics Corporation
On Wednesday, shares of United Therapeutics Corporation (NASDAQ: UTHR) experienced volatile short activity. After the activity, the stock price went up 4.31% to $228.39. The overall sentiment for UTHR has been Bullish.
Benzinga · 2d ago
Insider Sell: United Therapeutics
MT Newswires · 3d ago
United Therapeutics (UTHR) Gains on Tyvaso DPI Approval
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.
Zacks · 3d ago
United Therapeutics gets long-awaited FDA approval as competitor Liquidia takes stock hit
United Therapeutics saw its stock jump after receiving approval from the FDA to launch a new treatment for pulmonary arterial hypertension. Liquidia is pursuing a similar drug.
American City Business Journals · 4d ago
United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot'
United Therapeutics stock had its Relative Strength (RS) Rating upgraded from 71 to 89 Tuesday. On a weekly chart, the relative strength line for the biotech stock is sitting at a new high territory, earning it a Blue Dot in MarketSmith. This unique rati...
Investor's Business Daily · 4d ago
Top Healthcare Stocks for June 2022
These are the healthcare stocks with the best value, fastest growth, and most momentum for June 2022.
Investopedia · 4d ago
More
No Data
Learn about the latest financial forecast of UTHR. Analyze the recent business situations of Utd Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

45.45%Strong Buy
36.36%Buy
9.09%Hold
9.09%Under-perform
0.00%Sell
Analyst Price Target
The average UTHR stock price target is 242.50 with a high estimate of 300.00 and a low estimate of 140.00.
High300.00
Average242.50
Low140.00
Current 235.83
EPS
Actual
Estimate
1.262.523.775.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 621
Institutional Holdings: 48.38M
% Owned: 106.79%
Shares Outstanding: 45.30M
TypeInstitutionsShares
Increased
137
3.93M
New
60
495.61K
Decreased
152
2.90M
Sold Out
42
602.60K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Chief Executive Officer/Director
Martine Rothblatt
President/Chief Operating Officer
Michael Benkowitz
Non-Executive Vice Chairman/Lead Director/Independent Director
Christopher Patusky
Chief Financial Officer/Treasurer
James Edgemond
Executive Vice President/General Counsel/Secretary
Paul Mahon
Independent Director
Christopher Causey
Independent Director
Raymond Dwek
Independent Director
Richard Giltner
Independent Director
Katherine Klein
Independent Director
Raymond Kurzweil
Independent Director
Linda Maxwell
Independent Director
Nilda Mesa
Independent Director
Judy Olian
Independent Director
Louis Sullivan
Independent Director
Thomas Thompson
No Data
No Data
About UTHR
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. The Company market and sell four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution, which includes the Tyvaso Inhalation System; Orenitram (treprostinil) Extended-Release Tablets; and Adcirca (tadalafil) Tablets. In the United States, the Company also markets and sells an oncology product, Unituxin (dinutuximab) Injection, which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion.

Webull offers kinds of United Therapeutics Corporation stock information, including NASDAQ:UTHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UTHR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading UTHR stock methods without spending real money on the virtual paper trading platform.